José Sifuentes‐Osornio

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial”.

Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Rheumatology(2022)10.1016/s2665-9913(22)00044-3

N/A

1.8DataRank · unranked

47 citations

Martti Antila, Joachim H. Ficker, И. Г. Гордеев, Alfredo G. Guerreros, Amparo López‐Bernús +15 more

The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis

The Lancet Regional Health - Americas(2023)10.1016/j.lana.2023.100561

N/A

0.712DataRank · unranked

114 citations

Lucien Swetschinski, Nicole Davis Weaver, Kevin S Ikuta, Tomislav Meštrović, Authia P Gray +95 more